Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel)

被引：3
|
作者：
Nieto, Yago [1 ]
Anderlini, Paolo [1 ]
Popat, Uday [1 ]
Liu, Ping [1 ]
Andersson, Borje S. [1 ]
Shpall, Elizabeth J. [1 ]
Kebriaei, Partow [1 ]
Hosing, Chitra [1 ]
Alousi, Amin M. [1 ]
Qazilbash, Muzaffar H. [1 ]
Ciurea, Stefan O. [1 ]
Parmar, Simrit [1 ]
Champlin, Richard E. [1 ]
Jones, Roy [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.690.690
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [21] Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT)
    Nieto, Yago
    Bassett, Roland
    Hosing, Chitra
    Jones, Roy B.
    Valdez, Ben C.
    Kingham, Ashley
    Ahmed, Sairah
    Alousi, Amin M.
    Anderlini, Paolo
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Shpall, Elizabeth J.
    Kebriaei, Partow
    Brammer, Jonathan E.
    Oki, Yasuhiro
    Fanale, Michelle A.
    Maadani, Farzaneh
    Rondon, Gabriela
    Champlin, Richard E.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S227 - S228
  • [22] Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
    Hagen, Patrick
    Norton, Joseph
    Tsai, Stephanie
    Campo, Loredana
    Lee, Mary
    Gomez, Kayeromi
    Stiff, Patrick
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1422 - 1428
  • [23] High-dose etoposide, cytarabine and melphalan as conditioning regimen for autologous stem cell transplantation in patients with refractory or relapsed Hodgkin's lymphoma
    Bekadja, M. A.
    Osmani, S.
    Brahimi, M.
    Talhi, S.
    Bekadja, S.
    Belkhodja, S.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S446 - S446
  • [24] High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplantation (ASCT) in patients with primary refractory aggressive Non-Hodgkin's lymphoma
    Rodriguez, J
    Caballero, MD
    Solano, C
    Lahuerta, JJ
    Arranz, R
    Sureda, A
    Zuazu, J
    Marin, J
    García-Laraña, J
    López-Guillermo, A
    SanMiguel, J
    Conde, E
    BONE MARROW TRANSPLANTATION, 2001, 27 : S260 - S261
  • [25] Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
    Nieto, Yago
    Bassett, Roland
    Anderlini, Paolo
    Hosing, Chitra M.
    Alousi, Amin M.
    Popat, Uday R.
    Andersson, Borje S.
    Valdez, Benigno C.
    Shpall, Elizabeth J.
    Ahmed, Sairah
    Qazilbash, Muzaffar
    Guillermo, Maria
    Oki, Yasuhiro
    Fanale, Michelle A.
    Hagemeister, Fredrick B.
    Dabaja, Bouthaina S.
    Pinnix, Chelsea C.
    Milgrom, Sarah A.
    Tewari, Priti
    Champlin, Richard E.
    Jones, Roy
    BLOOD, 2015, 126 (23)
  • [26] Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
    Nieto, Yago
    Valdez, Benigno C.
    Thall, Peter F.
    Wei, Wei
    Jones, Roy
    Hosing, Chitra M.
    Ahmed, Sairah
    Popat, Uday R.
    Shpall, Elizabeth J.
    Qazilbash, Muzaffar
    Gulbis, Alison M.
    Anderlini, Paolo
    Shah, Nina
    Bashir, Qaiser
    Alousi, Amin M.
    Oki, Yasuhiro
    Hagemeister, Fredrick B.
    Champlin, Richard E.
    Andersson, Borje S.
    BLOOD, 2015, 126 (23)
  • [27] Tandem high-dose chemotherapy with thiotepa and busulfan–melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients
    C Pasqualini
    C Dufour
    G Goma
    M-A Raquin
    V Lapierre
    D Valteau-Couanet
    Bone Marrow Transplantation, 2016, 51 : 227 - 231
  • [28] Pulmonary mortality after high-dose oral busulfan and autologous stem cell transplant (ASCT) in patients with non-Hodgkin lymphoma (NHL).
    Kalaycio, M
    Pohlman, B
    Rybicki, L
    Sobecks, R
    Kuczkowski, E
    Andresen, S
    Brown, S
    Bolwell, B
    BLOOD, 2005, 106 (11) : 501A - 502A
  • [29] Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas
    Jae-Cheol Jo
    Jin-Seok Kim
    Je-Hwan Lee
    Jung-Hee Lee
    Seong Nam Im
    Sang-Min Lee
    Sung-Soo Yoon
    In-Ho Kim
    Seong Hwa Bae
    Yoo Jin Lee
    Yunsuk Choi
    Won-Sik Lee
    Annals of Hematology, 2021, 100 : 189 - 196
  • [30] Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas
    Jo, Jae-Cheol
    Kim, Jin-Seok
    Lee, Je-Hwan
    Lee, Jung-Hee
    Im, Seong Nam
    Lee, Sang-Min
    Yoon, Sung-Soo
    Kim, In-Ho
    Bae, Seong Hwa
    Lee, Yoo Jin
    Choi, Yunsuk
    Lee, Won-Sik
    ANNALS OF HEMATOLOGY, 2021, 100 (01) : 189 - 196
12345